Tag: EGFR,Erlotinib,NCCN Guidelines,NSCLC,Press Releases,Veristrat,blood-based cancer test,blood-based protein profiling test,cancer diagnostics,chemotherapy,liquid biopsy,lung cancer,oncology
-
Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines
Guidelines provide evidence-based, consensus-driven recommendations for managing cancer. Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, today announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer…